Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ARTELO BIOSCIENCES, INC. issued 292,398 shares of Common Stock of common stock to Square Gate Capital Master Fund, LLC – Series 5 for aggregate value, as of January 30, 2026, of $500,000.
- Security
- common stock
- Shares
- 292,398 shares of Common Stock
- Purchaser
- Square Gate Capital Master Fund, LLC – Series 5
- Consideration
- aggregate value, as of January 30, 2026, of $500,000
Exact text from the filing
In consideration for Square Gate’s execution and delivery of the Purchase Agreement, the Company will issue 292,398 shares of Common Stock to Square Gate (the “Commitment Shares”), having an aggregate value, as of January 30, 2026, of $500,000, as shares and/or as pre-funded warrants.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ARTELO BIOSCIENCES, INC. issued up to $25 million (the “Initial Commitment Amount”) in shares of common stock of common stock to Square Gate Capital Master Fund, LLC – Series 5 for 95% of the lowest daily VWAP of the Common Stock.
- Security
- common stock
- Shares
- up to $25 million (the “Initial Commitment Amount”) in shares of common stock
- Purchaser
- Square Gate Capital Master Fund, LLC – Series 5
- Consideration
- 95% of the lowest daily VWAP of the Common Stock
Exact text from the filing
applicable Put Date, or (iii) $500,000, subject to waiver by Square Gate in its sole discretion. The purchase price to be paid by Square Gate for the Regular Put Amount will be 95% of the lowest daily VWAP (as defined in the Purchase Agreement) of the Common Stock during the three trading days immediately following the applicable Put Date (the “Regular
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ARTELO BIOSCIENCES, INC. entered into Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5 valued at up to $25 million (effective 2026-01-30).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Square Gate Capital Master Fund, LLC – Series 5
- Value
- up to $25 million
- Effective
- 2026-01-30
Exact text from the filing
On January 30, 2026, Artelo Biosciences, Inc. (the “Company”) entered into an Equity Purchase Agreement, dated as of January 30, 2026 (the “Purchase Agreement”), with Square Gate Capital Master Fund, LLC – Series 5, a series limited liability company organized in the state of Delaware (“Square Gate”), pursuant to which the Company has the right, but not the obligation, to direct Square Gate to purchase up to $25 million (the “Initial Commitment Amount”) in shares of common stock
View on SEC.gov